Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
Retrieved on:
Tuesday, January 11, 2022
Patient, Research, LaSalle Street Station, Psilocybin, File, COVID-19, Safety, NASDAQ, GLOBE, Toronto Stock Exchange, Instagram, USPTO, Field trip, Patent, Solubility, Phrase, PCT, ISR, Private Securities Litigation Reform Act, TSX, Twitter, Family, China International Search and Rescue Team, TIHKAL, Risk, Toxicology, Pharmaceutical industry
17/364,047 for claims related to FT-104 (informally known as Isoprocin Glutarate), Field Trips first novel psychedelic molecule in development.
Key Points:
- 17/364,047 for claims related to FT-104 (informally known as Isoprocin Glutarate), Field Trips first novel psychedelic molecule in development.
- The international (PCT) patent application provides Field Trip with deferred patent filing rights in 150+ countries.
- Field Trip expects the patent for Tryptamine Prodrugs to be issued in February 2022 and it will expire in 2040.
- About Field Trip Health Ltd.
Field Trip is a global leader in the development and delivery of psychedelic therapies.